Abstract
Background & Aims Thrombocytopenia is common among patients with hepatitis C virus (HCV) infection and advanced fibrosis or cirrhosis, limiting initiation and dose of peginterferon-alfa (PEG) and ribavirin (RBV) therapy. The phase 3 randomized, controlled studies, Eltrombopag to Initiate and Maintain Interferon Antiviral Treatment to Benefit Subjects with Hepatitis C-Related Liver Disease (ENABLE)-1 and ENABLE-2, investigated the ability of eltrombopag to increase the number of platelets in patients, thereby allowing them to receive initiation or maintenance therapy with PEG and RBV. Methods Patients with HCV infection and thrombocytopenia (platelet count
| Original language | English |
|---|---|
| Journal | Gastroenterology |
| Volume | 146 |
| Issue number | 2 |
| DOIs | |
| Publication status | Published - Feb 2014 |
Fingerprint
Keywords
- Blood Clot
- Complication
- Liver Disease
- Portal Hypertension
ASJC Scopus subject areas
- Gastroenterology
Cite this
Eltrombopag increases platelet numbers in thrombocytopenic patients with hcv infection and cirrhosis, allowing for effective antiviral therapy. / Afdhal, Nezam H.; Dusheiko, Geoffrey M.; Giannini, Edoardo G.; Chen, Pei Jer; Han, Kwang Hyub; Mohsin, Aftab; Rodriguez-Torres, Maribel; Rugina, Sorin; Bakulin, Igor; Lawitz, Eric; Shiffman, Mitchell L.; Tayyab, Ghias Un Nabi; Poordad, Fred; Kamel, Yasser Mostafa; Brainsky, Andres; Geib, James; Vasey, Sandra Y.; Patwardhan, Rita; Campbell, Fiona M.; Theodore, Dickens.
In: Gastroenterology, Vol. 146, No. 2, 02.2014.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Eltrombopag increases platelet numbers in thrombocytopenic patients with hcv infection and cirrhosis, allowing for effective antiviral therapy
AU - Afdhal, Nezam H.
AU - Dusheiko, Geoffrey M.
AU - Giannini, Edoardo G.
AU - Chen, Pei Jer
AU - Han, Kwang Hyub
AU - Mohsin, Aftab
AU - Rodriguez-Torres, Maribel
AU - Rugina, Sorin
AU - Bakulin, Igor
AU - Lawitz, Eric
AU - Shiffman, Mitchell L.
AU - Tayyab, Ghias Un Nabi
AU - Poordad, Fred
AU - Kamel, Yasser Mostafa
AU - Brainsky, Andres
AU - Geib, James
AU - Vasey, Sandra Y.
AU - Patwardhan, Rita
AU - Campbell, Fiona M.
AU - Theodore, Dickens
PY - 2014/2
Y1 - 2014/2
N2 - Background & Aims Thrombocytopenia is common among patients with hepatitis C virus (HCV) infection and advanced fibrosis or cirrhosis, limiting initiation and dose of peginterferon-alfa (PEG) and ribavirin (RBV) therapy. The phase 3 randomized, controlled studies, Eltrombopag to Initiate and Maintain Interferon Antiviral Treatment to Benefit Subjects with Hepatitis C-Related Liver Disease (ENABLE)-1 and ENABLE-2, investigated the ability of eltrombopag to increase the number of platelets in patients, thereby allowing them to receive initiation or maintenance therapy with PEG and RBV. Methods Patients with HCV infection and thrombocytopenia (platelet count
AB - Background & Aims Thrombocytopenia is common among patients with hepatitis C virus (HCV) infection and advanced fibrosis or cirrhosis, limiting initiation and dose of peginterferon-alfa (PEG) and ribavirin (RBV) therapy. The phase 3 randomized, controlled studies, Eltrombopag to Initiate and Maintain Interferon Antiviral Treatment to Benefit Subjects with Hepatitis C-Related Liver Disease (ENABLE)-1 and ENABLE-2, investigated the ability of eltrombopag to increase the number of platelets in patients, thereby allowing them to receive initiation or maintenance therapy with PEG and RBV. Methods Patients with HCV infection and thrombocytopenia (platelet count
KW - Blood Clot
KW - Complication
KW - Liver Disease
KW - Portal Hypertension
UR - http://www.scopus.com/inward/record.url?scp=84892769466&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84892769466&partnerID=8YFLogxK
U2 - 10.1053/j.gastro.2013.10.012
DO - 10.1053/j.gastro.2013.10.012
M3 - Article
C2 - 24126097
AN - SCOPUS:84892769466
VL - 146
JO - Gastroenterology
JF - Gastroenterology
SN - 0016-5085
IS - 2
ER -